Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.

Tang XF, Wang J, Zhang JH, Meng XM, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yuan JQ, Yang YJ.

Eur J Clin Pharmacol. 2013 May;69(5):1103-12. doi: 10.1007/s00228-012-1446-8. Epub 2012 Nov 14.

PMID:
23150151
2.

Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.

Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T.

Thromb Res. 2015 Mar;135(3):449-58. doi: 10.1016/j.thromres.2014.12.007. Epub 2014 Dec 9. Review.

PMID:
25511576
3.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
4.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
5.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Epub 2013 Sep 27. Review.

6.

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP.

JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880. Review.

PMID:
22203539
7.

Genetic and nongenetic factors influencing the response to clopidogrel.

Notarangelo MF, Bontardelli F, Merlini PA.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S1-7. doi: 10.2459/JCM.0b013e328364bb04. Review.

PMID:
24378836
8.

Genetic determinants of on-clopidogrel high platelet reactivity.

Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R.

Platelets. 2011;22(6):399-407. doi: 10.3109/09537104.2011.579648. Epub 2011 May 31. Review.

PMID:
21627411
9.

Genetic determinants of platelet response to clopidogrel.

Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A.

J Thromb Thrombolysis. 2011 Nov;32(4):459-66. doi: 10.1007/s11239-011-0611-8. Review.

10.

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?

Kassimis G, Stavrou EF, Alexopoulos D, Athanassiadou A.

Curr Pharm Des. 2013;19(13):2489-95. Review.

PMID:
23360266
11.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Epub 2011 Dec 30. Review.

PMID:
22207144
12.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
13.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

14.

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.

Li Y, Tang HL, Hu YF, Xie HG.

J Thromb Haemost. 2012 Feb;10(2):199-206. doi: 10.1111/j.1538-7836.2011.04570.x. Review.

15.

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.

Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R.

Heart. 2012 Jan;98(2):100-8. doi: 10.1136/hrt.2011.227652. Epub 2011 Jun 21. Review.

PMID:
21693476
16.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
17.

The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.

Fefer P, Matetzky S.

Thromb Haemost. 2011 Aug;106(2):203-10. doi: 10.1160/TH11-04-0228. Epub 2011 Jul 12. Review.

PMID:
21792462
18.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Review. No abstract available.

19.

Genetic considerations.

Price MJ.

Adv Cardiol. 2012;47:100-13. doi: 10.1159/000338043. Epub 2012 Aug 9. Review.

PMID:
22906906
20.

Pharmacogenomics of antiplatelet drugs.

Sabatine MS, Mega JL.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):343-7. doi: 10.1182/asheducation-2014.1.343. Epub 2014 Nov 18. Review.

PMID:
25696877

Supplemental Content

Support Center